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Background
Hematospermia following prostate radiation therapy is a benign
and often self-limiting side effect. However, it may be
bothersome to some men and their partners with a negative
impact on sexual quality of life (QOL). This study sought to
evaluate the incidence, duration, and resolution of
hematospermia in patients following stereotactic body
radiation therapy (SBRT) for prostate cancer.

Methods
Retrospective review of 227 patients treated with SBRT (20132019) for localized prostate carcinoma with minimum two-years
follow. Exclusion: Patients >70 years, patient received hormonal
therapy. Hematospermia was defined as bright red blood in the
ejaculate. Data on hematospermia included duration,
resolution, and recurrence. Utilization of 5-alpha reductase
inhibitors was documented at each visit.

Hematospermia is a
bothersome, self-limiting
symptom experienced by a
small percentage of men
following prostate SBRT

227 patients (45 low-, 177 intermediate-, and 5 high-risk according
to the D’Amico classification). Median age of 65 years (range 4770). The 2-year cumulative incidence of hematospermia was 5.6%
(14 patients). All but one patient (93%) saw resolution of their
hematospermia by two years post-SBRT. The median time to
hematospermia was 9 months post-treatment. 10 patients with
hematospermia (70%) were managed with 5-alpha reductase
inhibitors. Hematospermia was transient in most patients with
70% of the men reporting resolution by the next follow-up visit.

Conclusions
The incidence of bothersome hematospermia following SBRT
was low. Hematospermia, as noted by other studies, often selfresolves. 5-alpha reductase inhibitors may lead to quicker
resolution of bothersome hematospermia
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